|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MED29 |
Gene summary for MED29 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MED29 | Gene ID | 55588 |
| Gene name | mediator complex subunit 29 | |
| Gene Alias | IXL | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NX70 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55588 | MED29 | LZE4T | Human | Esophagus | ESCC | 6.43e-11 | 4.22e-01 | 0.0811 |
| 55588 | MED29 | LZE5T | Human | Esophagus | ESCC | 1.56e-08 | 4.45e-01 | 0.0514 |
| 55588 | MED29 | LZE7T | Human | Esophagus | ESCC | 8.21e-13 | 4.33e-01 | 0.0667 |
| 55588 | MED29 | LZE8T | Human | Esophagus | ESCC | 6.31e-13 | 2.20e-01 | 0.067 |
| 55588 | MED29 | LZE20T | Human | Esophagus | ESCC | 6.53e-11 | 3.83e-01 | 0.0662 |
| 55588 | MED29 | LZE21D1 | Human | Esophagus | HGIN | 1.02e-04 | 6.12e-01 | 0.0632 |
| 55588 | MED29 | LZE24T | Human | Esophagus | ESCC | 3.38e-26 | 5.96e-01 | 0.0596 |
| 55588 | MED29 | LZE21T | Human | Esophagus | ESCC | 5.15e-06 | 2.91e-01 | 0.0655 |
| 55588 | MED29 | LZE6T | Human | Esophagus | ESCC | 3.57e-07 | 4.00e-01 | 0.0845 |
| 55588 | MED29 | P1T-E | Human | Esophagus | ESCC | 4.34e-38 | 1.95e+00 | 0.0875 |
| 55588 | MED29 | P2T-E | Human | Esophagus | ESCC | 1.37e-35 | 6.10e-01 | 0.1177 |
| 55588 | MED29 | P4T-E | Human | Esophagus | ESCC | 2.22e-27 | 5.17e-01 | 0.1323 |
| 55588 | MED29 | P5T-E | Human | Esophagus | ESCC | 9.76e-33 | 5.71e-01 | 0.1327 |
| 55588 | MED29 | P8T-E | Human | Esophagus | ESCC | 1.60e-47 | 8.40e-01 | 0.0889 |
| 55588 | MED29 | P9T-E | Human | Esophagus | ESCC | 2.82e-12 | 1.92e-01 | 0.1131 |
| 55588 | MED29 | P10T-E | Human | Esophagus | ESCC | 1.97e-37 | 6.05e-01 | 0.116 |
| 55588 | MED29 | P11T-E | Human | Esophagus | ESCC | 3.99e-23 | 9.34e-01 | 0.1426 |
| 55588 | MED29 | P12T-E | Human | Esophagus | ESCC | 9.62e-35 | 4.98e-01 | 0.1122 |
| 55588 | MED29 | P15T-E | Human | Esophagus | ESCC | 6.29e-32 | 5.25e-01 | 0.1149 |
| 55588 | MED29 | P16T-E | Human | Esophagus | ESCC | 2.96e-23 | 3.38e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MED29 | SNV | Missense_Mutation | rs765711223 | c.63N>C | p.Lys21Asn | p.K21N | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MED29 | SNV | Missense_Mutation | c.225C>G | p.Phe75Leu | p.F75L | protein_coding | tolerated(0.5) | probably_damaging(0.992) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MED29 | SNV | Missense_Mutation | c.285G>C | p.Leu95Phe | p.L95F | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| MED29 | SNV | Missense_Mutation | c.116N>G | p.Ser39Trp | p.S39W | protein_coding | deleterious(0.03) | possibly_damaging(0.877) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| MED29 | SNV | Missense_Mutation | novel | c.290A>G | p.Lys97Arg | p.K97R | protein_coding | tolerated(0.21) | benign(0.027) | TCGA-AA-3972-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD | |
| MED29 | SNV | Missense_Mutation | c.274C>A | p.Leu92Ile | p.L92I | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AA-A024-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| MED29 | SNV | Missense_Mutation | novel | c.218N>G | p.Gln73Arg | p.Q73R | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MED29 | SNV | Missense_Mutation | novel | c.356C>T | p.Pro119Leu | p.P119L | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| MED29 | SNV | Missense_Mutation | c.390C>A | p.Phe130Leu | p.F130L | protein_coding | deleterious(0.01) | possibly_damaging(0.514) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| MED29 | SNV | Missense_Mutation | novel | c.565N>G | p.Ile189Val | p.I189V | protein_coding | tolerated(0.47) | probably_damaging(0.981) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |